A recent mesothelioma study found the addition of bevacizumab to the chemotherapy treatment of pemetrexed plus cisplatin may increase the survival rate in patients. From 2008 to 2014, patients were given the standard treatment in 21-day increments for six cycles, with some receiving bevacizumab. The addition of bevacizumab increased survival[…]
Cisplatin (Platinol ®)
Study finds new treatment boosts chemotherapy results in mesothelioma
Researchers with the National Cancer Institute recently found an immunotoxin may increase the efficacy of chemotherapy. When combined with popular treatments cisplatin and pemetrexed, SS1P caused antitumor activity in patients. SS1P is an immunotoxin, a protein made by humans with a large targeting section linked to a toxin. Specifically, SS1P[…]
Mesothelioma treatments found in unlikely places
Scientists around the world work endlessly to discover new treatments for mesothelioma. Taking decades to develop, the asbestos-caused cancer leaves most with less than a year to live after diagnosis. Many studies focus on the effectiveness of current treatments, hoping to expand current knowledge and provide victims with the best[…]
New study suggests breast cancer drug may shrink mesothelioma tumors
After new evidence surfaced suggesting the enzyme aromatase is associated with malignant mesothelioma, Italian scientists began testing breast cancer drug Aromasin (exemestane) on mice and mesothelioma cells. Designed to inhibit aromatase, Aromasin curbs cell growth in breast cancer patients by helping reduce the amount of estrogen in the body. In[…]
Alimta remains best treatment for victims of malignant pleural mesothelioma
For those with inoperable malignant pleural mesothelioma, Alimta (permetrexed) combined with cisplatin remains the top treatment. Japanese researchers recently analyzed the results of 30 patients taking either Gemzar or the Alimta combination and compared complications, disease control and survival rates. Thirty mesothelioma cases were examined featuring 13 patients taking Gemzar[…]
Skip to content